All lobbying filings

Rare Disease Company Coalition

Rare Disease Company Coalition filed a Q1 amendment for Rare Disease Company Coalition on April 21, 2025.

Lobbying for Rare Disease Company Coalition · Healthcare

As filed: RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION.

All filings by Rare Disease Company Coalition · Everything Rare Disease Company Coalition has reported

Filing · LD-2 quarterly report Q1 amendment

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$60,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

HR 4758 - Accelerating Kids Access to Care Act

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024

Science/Technology

HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025

Bills named in this filing 6

H.R. 4758
Accelerating Kids’ Access to Care Act
H.R. 1262
Mikaela Naylon Give Kids a Chance Act
H.R. 946
ORPHAN Cures Act
H.R. 1414
Cameron’s Law
H.R. 7384
Creating Hope Reauthorization Act of 2024
H.R. 1532
Scientific EXPERT Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.